Although, the EMMY trial shows significant reduction of NT-proBNP levels inacute myocardial infarction compared to placebo, the trial was not powered forhard clinical endpoints like hospitalization for heart failure or mortality. This evidence concerns the gene NPPB and myocardial infarction.